Skip to main content
49°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
NeoGenomics, Inc. - Common Stock
(NQ:
NEO
)
9.535
-0.695 (-6.79%)
Streaming Delayed Price
Updated: 3:30 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NeoGenomics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
3 Small-Cap Stocks in Hot Water
March 12, 2025
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...
Via
StockStory
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
March 10, 2025
From
NeoGenomics, Inc.
Via
Business Wire
3 Healthcare Stocks Skating on Thin Ice
February 28, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,...
Via
StockStory
Topics
Stocks
Exposures
COVID-19
US Equities
What To Expect From RadNet’s (RDNT) Q4 Earnings
February 26, 2025
Diagnostic imaging company RadNet (NASDAQ:RDNT) will be reporting results tomorrow after market hours. Here’s what to look for.
Via
StockStory
Demystifying NeoGenomics: Insights From 6 Analyst Reviews
February 19, 2025
Via
Benzinga
5 Analysts Assess NeoGenomics: What You Need To Know
January 15, 2025
Via
Benzinga
Evaluating NeoGenomics: Insights From 4 Financial Analysts
December 10, 2024
Via
Benzinga
NeoGenomics to Participate in Upcoming Investor Conferences
February 24, 2025
From
NeoGenomics, Inc.
Via
Business Wire
Why NeoGenomics (NEO) Shares Are Trading Lower Today
February 18, 2025
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the company reported weak fourth-quarter results, with revenue falling below Wall...
Via
StockStory
NeoGenomics (NASDAQ:NEO) Misses Q4 Sales Targets
February 18, 2025
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 10.6% year on year to $172 million. On the other hand, the...
Via
StockStory
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
February 18, 2025
From
NeoGenomics, Inc.
Via
Business Wire
Earnings Scheduled For February 18, 2025
February 18, 2025
Via
Benzinga
NeoGenomics (NEO) To Report Earnings Tomorrow: Here Is What To Expect
February 17, 2025
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to look for.
Via
StockStory
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
January 29, 2025
From
NeoGenomics, Inc.
Via
Business Wire
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
January 17, 2025
Many stocks flashed buy signals as the major indexes rose to or above key levels.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance
January 15, 2025
The company expects sales to grow 12% to 13% annually in the long term.
Via
Investor's Business Daily
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
January 15, 2025
From
NeoGenomics, Inc.
Via
Business Wire
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
January 14, 2025
Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum
From
Adaptive Biotechnologies
Via
GlobeNewswire
NeoGenomics Shares Are Falling Today: What's Going On?
January 10, 2025
Shares of NeoGenomics, Inc. (NASDAQ: NEO) are, after the company announced that CEO Chris Smith will retire effective April 1 2025.
Via
Benzinga
NeoGenomics Announces Chief Executive Officer Succession
January 10, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
December 11, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
December 09, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
November 19, 2024
From
NeoGenomics, Inc.
Via
Business Wire
Felicia Williams Joins NeoGenomics Board of Directors
November 14, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 08, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports Third Quarter 2024 Results
November 05, 2024
From
NeoGenomics, Inc.
Via
Business Wire
Earnings Scheduled For November 14, 2024
November 14, 2024
Via
Benzinga
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
October 22, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
October 15, 2024
From
NeoGenomics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.